Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies

Biotechnology and Bioengineering

Volumn 108, Issue 6, 2011, Pages 1338-1346

  Teeters, Mark ^a   Bezila, Daniel ^a   Benner, Terry ^a   Alfonso, Pedro ^a   Alred, Patricia ^a  

^a Pharmaceutical Development and Manufacturing Sciences   (United States)

Author keywords

Excipient; Formulation; Modeling; Monoclonal antibody; Ultrafiltration diafiltration

Indexed keywords

BUFFER COMPOSITION; BUFFER PH; BULK DRUGS; DIAFILTRATION; EXCIPIENT; FORMULATION; LIQUID FORMULATIONS; MODEL-BASED; MODELING; MONOCLONAL ANTIBODIES (MABS); POISSON-BOLTZMANN EQUATIONS; PREDICTIVE MODELS; PROTEIN CHARGE; PROTEIN CONCENTRATIONS; RETENTATE; ROBUSTNESS TESTING; SOLUTION COMPOSITION; ULTRAFILTRATION/DIAFILTRATION; VOLUME EXCLUSION;

ALLERGIES; BOLTZMANN EQUATION; DESIGN OF EXPERIMENTS; FORECASTING; MERGERS AND ACQUISITIONS; MONOCLONAL ANTIBODIES; POISSON EQUATION; PROTEINS; SURFACE PLASMON RESONANCE;

SENSITIVITY ANALYSIS;

EXCIPIENT; MONOCLONAL ANTIBODY; PROTEIN;

ARTICLE; DIAFILTRATION; DRUG FORMULATION; MATHEMATICAL MODEL; PH; SENSITIVITY ANALYSIS; ULTRAFILTRATION;

ANTIBODIES, MONOCLONAL; EXCIPIENTS; IMMUNOGLOBULIN G; MODELS, CHEMICAL; ULTRAFILTRATION;

EID: 79954466263     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23067     Document Type: Article

References (15)

1. Bolton G, LaCasse D, Basha J, Boesch A, Esenther C, Acharya H, Godavarti R. 2008. Strategies for achieving buffer concentration, protein concentration and pH targets during the ultrafiltration of concentrated therapeutic protein. Presented at the 236th ACS National Meeting, Philadelphia, PA.
2. Capelle MAH, Gurny R, Arvinte T. 2007. High throughput screening of protein formulation stability: Practical considerations. Eur J Pharm Biopharm 65: 131-148.
3. Conway JH, Sloane NJA. 1993. Sphere packings, lattices, and groups, 2nd edn. New York: Springer-Verlag.
4. Creighton TE. 1983. Proteins: Structures and molecular principles. New York: W.H. Freeman.
5. Hunter RJ. 2001. Foundations of colloid science. New York: Oxford University.
6. Malmberg CG, Maryott AA. 1950. Dielectric constants of aqueous solutions of dextrose and sucrose. J Res Natl Bur Stand 45: 299-303.
7. Miao F, Velayudhan A, DiBella E, Shervin J, Felo M, Teeters M, Alred P. 2009. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody. Biotechnol Prog 25: 964-972.
8. Rathore N, Rajan RS. 2008. Current perspectives on stability of protein drug products during formulation fill and finish operations. Biotechnol Prog 24: 504-514.
9. Rathore AS, Winkle H. 2009. Quality by design for biopharmaceuticals. Nat Biotechnol 27: 26-34.
10. Shire SJ. 2009. Formulation and manufacturability of biologics. Curr Opin Biotechnol 20: 708-714.
11. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402.
12. Stoner MR, Fischer N, Nixon L, Buckel S, Benke M, Austin F, Randolph TW, Kendrick BS. 2004. Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations. J Pharm Sci 93: 2332-2342.
13. Verwey EJW, Overbeek JThG, 1948. Theory of the stability of lyophobic colloids. London: Elsevier.
14. Wang P, Anderko A. 2001. Computation of dielectric constants of solvent mixtures and electrolyte solutions. Fluid Phase Equilibr 186: 103-122.
15. Zhao H, Graf O, Milovic N, Luan X, Bluemel M, Smolny M, Forrer K. 2010. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 99: 2279-2294.